Global Cluster Headache Syndrome Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Cluster Headache Syndrome treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Clexio Biosciences Ltd, Crossject SA, Eli Lilly and Co, Novartis AG, Teva Pharmaceutical Industries Ltd and others.
A Significant contribution to the Cluster Headache Syndrome pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Cluster Headache Syndrome pipeline included 8 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Cluster Headache Syndrome condition and increased access to investments is encouraging growth of Cluster Headache Syndrome drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Cluster Headache Syndrome drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Cluster Headache Syndrome therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Cluster Headache Syndrome pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Cluster Headache Syndrome. Further, orphan drug status, fast track designation, grants awarded and other special status for Cluster Headache Syndrome pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Cluster Headache Syndrome pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Cluster Headache Syndrome Pipeline candidates-
A Significant contribution to the Cluster Headache Syndrome pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Cluster Headache Syndrome pipeline included 8 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Cluster Headache Syndrome condition and increased access to investments is encouraging growth of Cluster Headache Syndrome drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Cluster Headache Syndrome drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Cluster Headache Syndrome therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Cluster Headache Syndrome pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Cluster Headache Syndrome. Further, orphan drug status, fast track designation, grants awarded and other special status for Cluster Headache Syndrome pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Cluster Headache Syndrome pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Cluster Headache Syndrome Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Cluster Headache Syndrome drugs
- Late phase: Phase 3 and in-approval Cluster Headache Syndrome drugs
- Company overview
- Snapshot
- Cluster Headache Syndrome therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Cluster Headache Syndrome- Disease Overview
2.2 Cluster Headache Syndrome- Pipeline Snapshot
2.3 Cluster Headache Syndrome- Pipeline Drugs by Phase
2.4 Cluster Headache Syndrome- Pipeline Drugs by Company
2.5 Cluster Headache Syndrome- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Clexio Biosciences Ltd Cluster Headache Syndrome Drug Pipeline, H2- 2019
3.2 Crossject SA Cluster Headache Syndrome Drug Pipeline, H2- 2019
3.3 Eli Lilly and Co Cluster Headache Syndrome Drug Pipeline, H2- 2019
3.4 Novartis AG Cluster Headache Syndrome Drug Pipeline, H2- 2019
3.5 Teva Pharmaceutical Industries Ltd Cluster Headache Syndrome Drug Pipeline, H2- 2019
3.6 TrioxBio Inc Cluster Headache Syndrome Drug Pipeline, H2- 2019
3.7 Winston Pharmaceuticals Inc Cluster Headache Syndrome Drug Pipeline, H2- 2019
3.8 Zosano Pharma Corp Cluster Headache Syndrome Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Cluster Headache Syndrome- Phase 1 Drug Details
4.2 Cluster Headache Syndrome- Phase 1 Drug Overview
4.3 Cluster Headache Syndrome- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Cluster Headache Syndrome- Phase 2 Drug Details
5.2 Cluster Headache Syndrome- Phase 2 Drug Overview
5.3 Cluster Headache Syndrome- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Cluster Headache Syndrome- Phase 3 Drug Details
6.2 Cluster Headache Syndrome- Phase 3 Drug Overview
6.3 Cluster Headache Syndrome- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Cluster Headache Syndrome- Pre-clinical Phase Drug Details
7.2 Cluster Headache Syndrome- Pre-clinical Phase Drug Overview
7.3 Cluster Headache Syndrome- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Cluster Headache Syndrome- Disease Overview
2.2 Cluster Headache Syndrome- Pipeline Snapshot
2.3 Cluster Headache Syndrome- Pipeline Drugs by Phase
2.4 Cluster Headache Syndrome- Pipeline Drugs by Company
2.5 Cluster Headache Syndrome- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Clexio Biosciences Ltd Cluster Headache Syndrome Drug Pipeline, H2- 2019
3.2 Crossject SA Cluster Headache Syndrome Drug Pipeline, H2- 2019
3.3 Eli Lilly and Co Cluster Headache Syndrome Drug Pipeline, H2- 2019
3.4 Novartis AG Cluster Headache Syndrome Drug Pipeline, H2- 2019
3.5 Teva Pharmaceutical Industries Ltd Cluster Headache Syndrome Drug Pipeline, H2- 2019
3.6 TrioxBio Inc Cluster Headache Syndrome Drug Pipeline, H2- 2019
3.7 Winston Pharmaceuticals Inc Cluster Headache Syndrome Drug Pipeline, H2- 2019
3.8 Zosano Pharma Corp Cluster Headache Syndrome Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Cluster Headache Syndrome- Phase 1 Drug Details
4.2 Cluster Headache Syndrome- Phase 1 Drug Overview
4.3 Cluster Headache Syndrome- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Cluster Headache Syndrome- Phase 2 Drug Details
5.2 Cluster Headache Syndrome- Phase 2 Drug Overview
5.3 Cluster Headache Syndrome- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Cluster Headache Syndrome- Phase 3 Drug Details
6.2 Cluster Headache Syndrome- Phase 3 Drug Overview
6.3 Cluster Headache Syndrome- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Cluster Headache Syndrome- Pre-clinical Phase Drug Details
7.2 Cluster Headache Syndrome- Pre-clinical Phase Drug Overview
7.3 Cluster Headache Syndrome- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
